ABSTRACT Objective: To study the angiogenesis modulation mechanism of Xuefu Zhuyu Decoction (血府逐 瘀汤) on the endothelial cell line ECV304. Methods: ECV304 cells were treated with 2.5% Xuefu Zhuyu Decoction- 
Angiogenesis is important for the treatment and prognosis of ischemic diseases. Xuefu Zhuyu Decoction (血府逐瘀汤, XFZYD, driving out stasis from the mansion of blood decoction) was first recorded in 1830 in WANG Qing-ren's Correction of the Errors of Medical Works (Yi Lin Gai Cuo). It is a classical formula for activating blood and removing stasis and is composed of the following ingredients: Angelica sinensis (Oliv.) Diels 9 g, Rehmannia glutinosa Libosch. 9 g, Prunus persica 12 g, Carthamus tinctorius L. 9 g, Citrus aurantium L. 6 g, Paeonia lactiflora Pall. 6 g, Bupleurum chinese DC. 3 g, Glycyrrhiza uralensis Fisch. 6 g, Platycodon grandiflorum 4.5 g, Ligusticum Chuanxiong Hort. 4.5 g, and Cyathula officinalis Kuan 9 g.
Our previous work demonstrated that XFZYD has angiogenesis effects that not only increase the vessel number in chicken embryo chorioallantoic membrane (CAM) model, (1) but also mobilize marrow endothelial progenitor cell (EPC) (2, 3) and promote EPC differentiation (4) and tube formation. (5) The mechanism of its pro-angiogenesis is unclear. The current study was designed to explore the regulatory mechanism of XFZYD on angiogenesis. We first examined relevant endothelial cell migration, proliferation, adhesion and tube formation with endothelial cell line ECV304 to demonstrate the angiogenesis effect of XFZYD. We then used microarray technique to analyze changes in gene expression profiles following XFZYD treatment.
METHODS

Preparation of XFZYD-Containing Serum
XFZYD-containing serum was made according to the protocol adopted in our previous study. 
Incubation and Grouping of ECV304
Endothelial cell line ECV304 (China Center of Type Culture Collection, Wuhan University, China) was cultured in M199 containing 5% fetal bovine serum (FBS) (v/v) 
Cell Viability Assay
The effect of XFZYD-CS in inducing ECV304 proliferation was estimated by methyl thiazolyl tetrazolium (MTT) assay. MTT (5 mg/mL) was added to each well and incubated for 4 h. After the MTT solution was discarded and replaced by 200 μL dimethyl sulfoxide (DMSO), the plates were shaken for 10 min. The optical density (OD) was assessed at 570 nm (reference wave, 630 nm) using a 96-well microplate reader (BioTek Co., USA).
Cell Proliferation Assay
Cell proliferation assay was tested by FACS as described in the instruction book of Cycle TEST™ plus DNA REAGENT Kit (Becton Dickinson, USA). Cell Quest software (Becton Dickinson, USA) was used to acquire data, and ModiFit version 3.0 (Becton Dickinson, USA) was used for analysis.
Cell Migration Assay
Cell migration was evaluated by Boyden chamber assay. The upper chamber was covered by an 8 μm polycarbonate membrane. ECV304 cells (2×10 4 cells/ well) were suspended in 100μL corresponding serum and added on the membrane. The lower chamber was loaded with 100μL corresponding cell culture supernatant. After incubation at 37 ℃ for 16 h, the residual cells on the upper side of the membrane were removed with cotton swabs, and the membrane fixed with 4% neutral formalin for 10 min and stained with hematoxylin. The stained cells from 6 high power fields (HPF, ×200) were counted. Photographs were taken by an inverted phase contrast microscope (IX70, Olympus Co., Japan).
Cell Adhesion Assay
The 96-well plates were coated with 1% gelatin for 1 h. XFZYD-CS-treated or control serumtreated ECV304 cells (1×10 4 cells/well) were plated with 5% FBS for 30 min. The culture medium was subsequently removed and adherent cells from 6 random fields (×100) were counted.
In Vitro Tube Formation Assay
Matrigel assay was used to evaluate capillary tube formation as described in the protocol of in vitro angiogenesis assay kit (Millipore Co., USA). Briefly, ECMatrix™ solution was thawed on ice overnight, then mixed with diluent and placed in a 96-well plate at 37 ℃ for 2 h to allow the matrix solution to solidify. Each group of ECV304 cells was added on the polymerized matrigel at 1x10 4 cells per well.
After incubation at 37 ℃ for 10 h, capillary tubes were inspected at a magnification of 200× with an inverted phase contrast microscope. Capillary tubes were defined as endothelial cord formations that were connected at both ends. The number of tubes in six random fields per well was determined.
Real-Time Polymerase Chain Reaction Microarray
RNA of ECV304 cells was prepared by Trizol, its yield and quality assessed by UV absorbance and denaturing agarose gel electrophoresis, respectively. The first strand cDNA was synthesized by reverse transcriptase (Invitrogen Co., USA), diluted and loaded for the 96-well real-time polymerase chain reaction (RT-PCR) arrays (SuperArray Co., USA). All assays were performed according to the manufacturer's protocols.
Statistical Analysis
Data analysis of PCR array adopted the △△Ct Method. △Ct and △△Ct were calculated as follows: △Ct = average Ct -average Ct of house-keeping genes, △△Ct = △Ct (XFZYD group)-△Ct (control group). The fold-change for each gene was calculated as 2 -△△Ct . If the fold-change is greater than 1, then the result may be reported as a fold up-regulation. If the fold-change is less than 1, then the negative inverse of the result may be reported as a fold down-regulation. Significance was set at fold difference 2. For continuous variables, Student's t-test was used for two group comparison and oneway ANOVA for comparisons of more than two groups. Significance was accepted as P<0.05.
RESULTS
Effect of XFZYD-CS on Cell Viability
At 48 h, the cell viability as measured by MTT colorimetric assay was significantly higher for 2.5% XFZYD-CS treated ECV304 cells compared to the control cells. The cell viability was similar between the treated and control cells at 24 and 72 h time points (Table 1) .
Effect of XFZYD-CS on Cell Proliferation
At 48 h, significantly more proliferating cells were observed in XFZYD-CS treated ECV304 cells compared to the control cells as measured by flow cytometry. No difference in cell proliferation was observed at 24 h and 72 h ( Table 1) .
Effect of XFZYD-CS on Cell Migration
At 24, 48 and 72 h, the number of XFZYD-CS treated ECV304 cells migrating to the underlayer of the membrane were more than that of the control group ( Table 1) .
Effect of XFZYD-CS on Cell Adhesion
At 48 h, XFZYD-CS treatment significantly elevated the number of cells adherent on gelatin compared to the control group. There was no different in cell adhesion at 24 h and 72 h ( Table 1) .
Effect of XFZYD-CS on Tube Formation
In vitro angiogenesis assay showed that only at 48 h did XFZY-CS dramatically increase the tube number compared to controls. No difference was observed at 24 h and 72 h ( Table 1) .
Results of RT-PCR Microarray
Microarray analysis illustrated that among the 84 angiogenesis regulator genes chosen, the expression of 27 genes including 22 pro-angiogenesis and 5 antiangiogenesis factors had been affected significantly as defined by a change of 2 folds or higher in at least one time point, and among which, the expression of 18, 14 and 16 genes were affected at 24 h, 48 h and 72 h, respectively. Although the most obvious cellular changes associated with angiogenesis were observed at 48 h time point, the changes in gene expression appeared to occur as early as 24 h. The expression of 6 genes showed significant changes ( 2-fold increase or decrease) that were consistent at all three time points. Among the 6 genes, 2 pro-angiogenesis genes including transforming growth factorβ2 (TGFβ2) and vascular endothelial growth factor C (VEGFC) were up-regulated; and 3 pro-angiogenesis genes including chemokine (C-X-C motif) ligand 6 (CXCL6), cadherin 5 (CDH5), epidermal growth factor (EGF) and antiangiogenesis gene CXCL10 were down-regulated. The expression of 7 genes had changes in the same direction at all 3 time points but significant changes were observed either at 48 h or at 24 h or 72 h but not all 3 time points. Among these genes, ephrin A1 (EFNA1), CXCL5 and thrombospondin 2 (THBS2) were significantly down-regulated at 48 h; whereas EFNB2, thymidine phosphorylase (TYMP), fibroblast growth factor 2 (FGF2) and neuropilin 1 (NRP1) were significantly up-regulated at 24 h and 72 h. Additional genes with significant changes in expression at 48 h included inhibitor of DAN binding 3 (ID3) and interferon alpha 1 (INFA1) that were up-regulated, and chemokine ligand (CCL11), collagen type Ⅳ alpha 3 (COL4A3) and integrin beta 3 (ITGB3) that was downregulated (Tables 2-3) .
DISCUSSION
By comprehensive screening every aspect of endothelial cells in the process of angiogenesis including cell viability, proliferation, migration, adhesion and tube formation, this experiment demonstrated that at 48 h XFZYD-CS treatment had significant effects in all steps of the process. The 48 h was the optimal time point for angiogenesis while at 24 h and 72 h only cell migration was affected. There was not only an optimal time but also optimal concentration (6) as 2.5% XFZYD-containing serum used in this research in angiogenesis induced by XFZYD that made the time and dose-response curve resemble an inverted U which meaned the Among the genes whose expression had changed at the 3 time points in the 84 angiogenesis regulators, the Eph super family interested us most. EphA1 and EphB2 are both pro-angiogenesis, their expression was affected differently in the presence of XFZYD with EphA1 down-regulated and EphB2 up-regulated. In recent years it has become known that Eph receptor and ephrin interactions also regulate critical steps of angiogenesis, blood vessel formation and remodeling during vascular development. (8) (9) (10) EphrinA1 was the first member of the gene family that was isolated from cultured human umbilical vein endothelial cells. (10) (11) (12) It has a major impact on endothelial cell behavior and can modulate capillary sprout formation in the rat cornea assay and promote capillary-tube formation in in vitro angiogenesis assays. (10) EphrinB2 is also a key factor in both vascular development (13, 14) and postnatal angiogenesis. (15, 16) In our experiment, the differential regulation of EphA1 and EphB2 by XFZYD may reflect different roles of Eph family members in angiogenesis. Again, a more definitive understanding will require further research.
Angiogenesis is a highly complex process which is regulated by numerous positive and negative factors. Common positive factors include vascular endothelial growth factor, transforming growth factor, epithelial growth factor and fibroblast growth factor (17) and common negative factors include angiostatin, endostatin, and thrombospondin, etc. (18, 19) Balance Note: a Results shown are representative of three experiments angiogenesis effect was the best in the middle. This was quite different from a pure angiogenesis factor such as vascular endothelial growth factor (VEGF) etc. Previous clinical and laboratory research showed that XFZYD could promote angiogenesis while also between angiogenesis promoting factors and inhibitors allows healthy angiogenesis to occur only in embryonic development, wound healing and female reproductive cycle. Any imbalance will lead to pro-angiogenesis or anti-angiogenesis. Pro-angiogenesis is caused by the inadequate production of angiogenesis inhibitors and/or excessive amounts of angiogenesis growth factors. Our experimental results may reflect not only the imbalance but also the complicated modulation of proangiogenesis. XFZYD did not elevate all positive factors, for example, it up-regulated VEGFC and TGFB2 but down-regulated EGF, the same differential effect also applied to the inhibitors as IFNA1 upregulated but CXCL10 down-regulated and the end result was pro-angiogenesis.
In conclusion, our study showed that the angiogenesis mechanism of this classical Chinese herbal formula was multi-level, multi-targeted and had multiple pathways. The intriguing findings of altered gene expression provide a molecular basis of XFZYD in the treatment of ischemic disease and point to the direction for further research linking the angiogenesis mechanism to its clinical benefit.
